Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents
Authors:
- John F. MillerJMJohn F. Miller
- Elizabeth M. TurnerETElizabeth M. Turner
- Kristjan S. GudmundssonKGKristjan S. Gudmundsson
- Stephen JenkinsonSJStephen Jenkinson
- Andrew SpaltensteinASAndrew Spaltenstein
- Michael ThomsonMTMichael Thomson
- Pat WheelanPWPat Wheelan
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (7) , 2125-2128
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1Bioorganic & Medicinal Chemistry Letters, 2009
- Treatment of HIV infection with raltegravirExpert Opinion on Pharmacotherapy, 2009
- Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2009
- Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1Clinical Infectious Diseases, 2009
- HIV-1 entry inhibitors: an overviewCurrent Opinion in HIV and AIDS, 2009
- Recent patents regarding the discovery of small molecule CXCR4antagonistsExpert Opinion on Therapeutic Patents, 2009
- HIV entry inhibitors and their potential in HIV therapyMedicinal Research Reviews, 2008
- HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic optionsJournal of Antimicrobial Chemotherapy, 2008
- Overcoming resistance to existing therapies in HIV‐infected patients: The role of new antiretroviral drugsJournal of Medical Virology, 2008
- Coping with HIV Treatment Side Effects: Conceptualization, Measurement, and LinkagesAIDS and Behavior, 2007